臨床醫學研究所

Keyphrases

1. Hepatocellular Carcinoma 100%
2. Taiwan 54%
3. Confidence Interval 33%
4. Hazard Ratio 23%
5. Hepatitis C Virus 23%
6. Mesenchymal Stem Cells 20%
7. Hepatocellular Carcinoma Patients 20%
8. Hepatitis C 19%
9. Chronic Hepatitis C 19%
10. Cirrhosis 18%
11. Endothelial Progenitor Cells 18%
12. Overall Survival 17%
13. Migraine 17%
14. Risk Factors 16%
15. Head-and-neck Squamous Cell Carcinoma (HNSCC) 15%
16. Head-and-neck Cancer 14%
17. Transarterial Chemoembolization 14%
18. Hepatitis B Virus 14%
19. Human Mesenchymal Stem Cells (hMSCs) 14%
20. Reversible Cerebral Vasoconstriction Syndrome 13%
21. Clinical Outcomes 13%
22. Chronic Hepatitis B 13%
23. Hepatitis B Surface Antigen (HBsAg) 13%
24. Human Immunodeficiency Virus Type 1 (HIV-1) 13%
25. National Cohort Study 12%
26. Human Endothelial Progenitor Cells 12%
27. Taiwanese 12%
28. Prognostic Factors 12%
29. Multivariate Analysis 11%
30. Epithelial-mesenchymal Transition 11%
31. Ruptured Abdominal Aortic Aneurysm (rAAA) 11%
32. Radiofrequency Ablation 10%
33. Albumin-bilirubin Grade 10%
34. Chronic Kidney Disease 10%
35. High Risk 10%
36. Direct-acting Antivirals 10%
37. Odds Ratio 9%
38. Sustained Virological Response 9%
39. Stem Cells 9%
40. Surgical Resection 9%
41. Chronic Migraine 9%
42. Headache 9%
43. Chemotherapy 9%
44. Alpha-fetoprotein 8%
45. Tumor 8%
46. Chronic Hepatitis B Patients 8%
47. Hepatitis C Virus Infection 8%
48. Cardiovascular Events 8%
49. Hepatitis B e Antigen (HBeAg) 8%
50. Cancer Cells 8%
51. Mesenchymal Stromal Cells 7%
52. Taipei 7%
53. Immune Checkpoint Inhibitors 7%
54. Oral Tongue Squamous Cell Carcinoma (OTSCC) 7%
55. Macrophages 7%
56. Barcelona Clinic Liver Cancer 7%
57. Metastasis 7%
58. Osteogenic Differentiation 7%
59. Angiogenesis 7%
60. COVID-19 7%
61. Advanced Hepatocellular Carcinoma 7%
62. Hepatocellular Carcinoma Risk 7%
63. Liver 7%
64. Arteriovenous Fistula 7%
65. Treatment Outcome 7%
66. Cell Function 7%
67. Coronary Artery Bypass Grafting 7%
68. Gag-Pol 6%
69. Acute Myocardial Infarction 6%
70. Type 1 Diabetes Mellitus (T1DM) 6%
71. Hepatitis B 6%
72. Inflammation 6%
73. Acute Kidney Injury 6%
74. All-cause Mortality 6%
75. Liver Cirrhosis 6%
76. Antiretroviral Therapy 6%
77. Propensity Score Analysis 6%
78. Cirrhotic Patients 6%
79. Neovascularization 6%
80. Ischemic Stroke 6%
81. Virus 6%
82. Oxidative Stress 6%
83. Unresectable Hepatocellular Carcinoma 6%
84. Major Adverse Cardiovascular Events 6%
85. Percutaneous Coronary Intervention 6%
86. MELD Score 5%
87. Cox Proportional Hazards Model 5%
88. Meta-analysis 5%
89. Coronary Artery Disease 5%
90. Performance Status 5%
91. Overexpression 5%
92. Ischemia 5%
93. Adjusted Hazard Ratio 5%
94. Estimated Glomerular Filtration Rate 5%
95. Tumor Recurrence 5%
96. Hemodialysis Patients 5%
97. Cardiovascular Disease 5%
98. Non-diabetic 5%
99. Tumor Necrosis Factor-α 5%
100. Progression-free Survival 5%

Medicine and Dentistry

1. Hepatocellular Carcinoma 96%
2. Neoplasm 22%
3. Liver Cirrhosis 19%
4. Hazard Ratio 18%
5. Hepatitis B Virus 18%
6. Surgery 17%
7. Mesenchymal Stem Cell 16%
8. Hepatitis C Virus 16%
9. Overall Survival 16%
10. Transcatheter Arterial Chemoembolization 15%
11. Endothelial Progenitor Cell 15%
12. Cardiovascular System 14%
13. Chronic Hepatitis C 14%
14. Diseases 13%
15. Coronary Artery Disease 13%
16. Chronic Hepatitis B 12%
17. Bilirubin 12%
18. Migraine 11%
19. Hepatitis C 11%
20. Cohort Analysis 11%
21. Malignant Neoplasm 11%
22. Infection 10%
23. Diabetes Mellitus 10%
24. Chronic Kidney Disease 10%
25. Prevalence 10%
26. Proportional Hazards Model 9%
27. Liver Cancer 9%
28. Recurrent Disease 9%
29. Headache 9%
30. Radiofrequency Ablation 8%
31. Multivariate Analysis 8%
32. Hemodialysis 8%
33. Odds Ratio 8%
34. Prognostic Factor 8%
35. Head and Neck Squamous Cell Carcinoma 8%
36. Aortic Dissection 8%
37. Metastatic Carcinoma 7%
38. Hepatitis B 7%
39. In Vitro 7%
40. Acute Kidney Injury 7%
41. Abdominal Aortic Aneurysm 7%
42. Arteriovenous Fistula 7%
43. Cancer Staging 7%
44. Cardiovascular Disease 7%
45. Antiviral Therapy 7%
46. Platelet 6%
47. Endovascular Aneurysm Repair 6%
48. Antiviral Drug 6%
49. Head and Neck Cancer 6%
50. Cancer 6%
51. Kidney Function 6%
52. Survival Rate 6%
53. Reversible Cerebral Vasoconstriction Syndrome 6%
54. Fibrosis 6%
55. Coronary Artery Bypass Graft 6%
56. Biological Marker 6%
57. Stem Cell 6%
58. Angiogenesis 6%
59. Liver Disease 5%
60. End Stage Renal Disease 5%
61. Immune Checkpoint Inhibitor 5%
62. Percutaneous Coronary Intervention 5%
63. Computer Assisted Tomography 5%
64. Stent-Graft 5%
65. Apoplexy 5%
66. Immunotherapy 5%
67. Squamous Cell Carcinoma 5%